Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2011
09/01/2011US20110212937 Compounds for the reduction of beta-amyloid production
09/01/2011US20110212936 High-valent palladium fluoride complexes and uses thereof
09/01/2011US20110212935 Compositions and treatment methods-4
09/01/2011US20110212934 Pharmaceutical preparations for treatments of diseases and disorders of the breast
09/01/2011US20110212933 Antiseptic Compositions for the Treatment of Infections
09/01/2011US20110212932 Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation
09/01/2011US20110212931 Antioxidant
09/01/2011US20110212930 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
09/01/2011US20110212929 Protein Kinase Inhibitors
09/01/2011US20110212928 Methods and compositions for improving cognitive function
09/01/2011US20110212927 Carbonate prodrugs and methods of using the same
09/01/2011US20110212926 Water-soluble acetaminophen analogs
09/01/2011US20110212925 Novel compounds as receptor modulators with therapeutic utility
09/01/2011US20110212924 Compositions and methods to treat cardiac diseases
09/01/2011US20110212923 Phosphate Derivatives of Substituted Benzoxazoles
09/01/2011US20110212922 Processes for the preparation of phosphatide salts
09/01/2011US20110212921 Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof
09/01/2011US20110212920 N-Substituted Benzene Sulfonamides
09/01/2011US20110212919 Protein cross-linking inhibitor
09/01/2011US20110212918 Boron-containing small molecules
09/01/2011US20110212917 Agent for ameliorating brain hypofunction
09/01/2011US20110212916 Method and means for improving bowel health
09/01/2011US20110212915 Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
09/01/2011US20110212914 Stabilized pentosan polysulfate (pps) formulations and methods of analyzing them
09/01/2011US20110212913 Therapeutic compositions comprising phenolic acids for treating conditions related to inappropriate platelet aggregation
09/01/2011US20110212912 Optimised formulation of tobramycin for aerosolization
09/01/2011US20110212911 Transcription factor inhibitors and related compositions, formulations and methods
09/01/2011US20110212910 Antioxidant
09/01/2011US20110212909 Use of Ginsenoside Compound K in the Preparation of a Medicament for the Prevention and Treatment of Atherosclerosis
09/01/2011US20110212908 Topical compositions and the use thereof
09/01/2011US20110212907 Hexadecasaccharides with antithrombotic activity, including a covalent bond and an amino chain
09/01/2011US20110212906 C-linked glucuronide of n-(4-hydroxybenzyl) retinone, analogs thereof, and methods of using the same to inhibit neoplastic cell growth
09/01/2011US20110212905 Crystalline form of 1-(beta-d-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
09/01/2011US20110212904 Galactosylated pro-drugs of non-steroidal anti-inflammatories with improved pharmacokinetic characteristics and reduced toxicity of the starting drug
09/01/2011US20110212895 Treatment of Cognitive and Learning Impairment
09/01/2011US20110212892 Agent for treatment of diabetes
09/01/2011US20110212888 Diet and methods for improving learning capacity, mood and behavior in mammals
09/01/2011US20110212449 Distinguishing pca3 messenger rna species in benign and malignant prostate tissues
09/01/2011US20110212243 Parenteral selenomethionine for production of selenium-rich foods
09/01/2011US20110212200 Agent for treating eye diseases
09/01/2011US20110212199 Agent for treating eye diseases
09/01/2011US20110212196 Therapeutic oil composition containing carvone
09/01/2011US20110212194 Composition for Inhibiting Melanogenesis and Use Thereof
09/01/2011US20110212192 Ingestibles containing sugar and cinnamon or ginseng
09/01/2011US20110212191 Composition for the maintenance of blood sugar levels comprising cinnamon and ginseng
09/01/2011US20110212188 Preventing and/or treating cardiovascular disease and/or associated heart failure
09/01/2011US20110212186 Composition for treating autoimmune disorders
09/01/2011US20110212182 Masked taste pharmaceutical granules/granulates
09/01/2011US20110212181 Compositions and methods for treating chronic respiratory inflammation
09/01/2011US20110212180 Method of producing microcapsules
09/01/2011US20110212178 Injectable Hydrogel Filaments For Biomedical Uses
09/01/2011US20110212176 Ciclopirox and cytarabine for the treatment of leukemic disorders
09/01/2011US20110212175 Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor
09/01/2011US20110212174 Controlled release arginine formulations
09/01/2011US20110212173 Controlled Release Treatment of Depression
09/01/2011US20110212172 Administration of an adsorbent polymer for treatment of systemic inflammation
09/01/2011US20110212171 Taste masked topiramate composition and an orally disintegrating tablet comprising the same
09/01/2011US20110212170 Formulation For Retinoid-Containing Soft Gelatin Capsules
09/01/2011US20110212169 METHOD FOR PRODUCING POWDER CONTAINING NANOPARTICULATED SPARINGLY SOLUBLE DRUG, POWDER PRODUCED THEREBY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME (As Amended)
09/01/2011US20110212167 Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof
09/01/2011US20110212166 Carnitine conjugates of adamantanamines derivatives as dual prodrugs for various uses
09/01/2011US20110212165 Pharmaceutical compositions of the isolated d-enantiomer of the quinazolinone derivative halofuginone
09/01/2011US20110212161 Treatment skin disorders
09/01/2011US20110212157 Dermal delivery
09/01/2011US20110212156 Use of a mixture of two or more enteric materials to regulate drug release via membrance or matrix for systemic therapeutics
09/01/2011US20110212154 Biodegradable Implantable Drug Delivery Device
09/01/2011US20110212150 Process for the treatment of cellulosic molded bones
09/01/2011US20110212146 Compositions
09/01/2011US20110212142 Curcuminoids and its metabolites for the application in ocular diseases
09/01/2011US20110212141 Injectable depot formulation comprising crystals of iloperidone
09/01/2011US20110212140 Pressure-sensitive adhesive composition applicable to nail and adhesive agent for nail
09/01/2011US20110212138 Sustained release formulations using non-aqueous carriers
09/01/2011US20110212137 Inhalable pharmaceutical composition
09/01/2011US20110212135 Oligodeoxynucleotide and its use to induce an immune response
09/01/2011US20110212115 Melk epitope peptides and vaccines containing the same
09/01/2011US20110212110 Compositions and Methods for Detecting TLR3
09/01/2011US20110212108 Neuregulin/erbb signaling and integrin
09/01/2011US20110212107 Juvenile hemochromatosis gene (HFE2A) cleavage products and uses thereof
09/01/2011US20110212106 Hiv-1 neutralizing antibodies and uses thereof
09/01/2011US20110212103 Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
09/01/2011US20110212102 Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions
09/01/2011US20110212100 Methods for modulating development and expansion of il-17 expressing cells
09/01/2011US20110212098 Novel Melanoma Antigen Peptide and Uses Thereof
09/01/2011US20110212097 Methods and Compositions to Treat and Detect Misfolded-SOD1 Mediated Diseases
09/01/2011US20110212090 Combinatorial Analysis and Repair
09/01/2011US20110212089 Targeting pax2 for the treatment of breast cancer
09/01/2011US20110212083 Role of soluble upar in the pathogenesis of proteinuric kidney disease
09/01/2011US20110212081 Krüppel-like factors and fat regulation
09/01/2011US20110212080 Urea derivatives as antibacterial agents
09/01/2011US20110212079 Adaptive biochemical signatures
09/01/2011US20110212078 Synthesis and use of heterocyclic antibacterial agents
09/01/2011US20110212077 Bi-aryl meta-pyrimidine inhibitors of kinases
09/01/2011US20110212076 Viral Therapeutic
09/01/2011US20110212072 Inhibitors of Fatty Acid Oxidation for Prophylaxis and Treatment of Diseases Related to Mitochondrial Dysfunction
09/01/2011US20110212058 Targeted modulation of gene expression
09/01/2011US20110212056 Combination therapy for the treatment of liver diseases
09/01/2011US20110212054 Thrombopoietin mimetics
09/01/2011US20110212053 Phosphatidylinositol 3 kinase inhibitors
09/01/2011US20110212050 Side-chain crystallizable polymers for medical applications
09/01/2011US20110212049 Polymer compositions of dihydroxyacetone and uses thereof